VU 0361737
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531331

CAS#: 1161205-04-4

Description: VU 0361737, also known as ML128, is a selective positive allosteric modulator at mGluR-4 (EC50 values are 240 and 110 nM at human and rat receptors respectively).


Chemical Structure

img
VU 0361737
CAS# 1161205-04-4

Theoretical Analysis

MedKoo Cat#: 531331
Name: VU 0361737
CAS#: 1161205-04-4
Chemical Formula: C13H11ClN2O2
Exact Mass: 262.0509
Molecular Weight: 262.693
Elemental Analysis: C, 59.44; H, 4.22; Cl, 13.49; N, 10.66; O, 12.18

Price and Availability

Size Price Availability Quantity
100.0mg USD 450.0 2 Weeks
200.0mg USD 650.0 2 Weeks
500.0mg USD 1250.0 2 Weeks
1.0g USD 2150.0 2 Weeks
2.0g USD 3850.0 2 Weeks
Bulk inquiry

Synonym: VU 0361737, VU-0361737, VU0361737; ML128; ML-128; ML 128;

IUPAC/Chemical Name: N-(4-Chloro-3-methoxyphenyl)-2-pyridinecarboxamide

InChi Key: ARYUXFNGXHNNDM-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H11ClN2O2/c1-18-12-8-9(5-6-10(12)14)16-13(17)11-4-2-3-7-15-11/h2-8H,1H3,(H,16,17)

SMILES Code: O=C(C1=NC=CC=C1)NC2=CC=C(Cl)C(OC)=C2

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 262.693 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lindqvist D, Dhabhar FS, James SJ, Hough CM, Jain FA, Bersani FS, Reus VI, Verhoeven JE, Epel ES, Mahan L, Rosser R, Wolkowitz OM, Mellon SH. Oxidative stress, inflammation and treatment response in major depression. Psychoneuroendocrinology. 2016 Nov 30;76:197-205. doi: 10.1016/j.psyneuen.2016.11.031. [Epub ahead of print] PubMed PMID: 27960139.

2: Lusli M, Peters R, van Brakel W, Zweekhorst M, Iancu S, Bunders J, Irwanto, Regeer B. The Impact of a Rights-Based Counselling Intervention to Reduce Stigma in People Affected by Leprosy in Indonesia. PLoS Negl Trop Dis. 2016 Dec 13;10(12):e0005088. doi: 10.1371/journal.pntd.0005088. PubMed PMID: 27959932.

3: Zhang L, Chen XL, Hu Q, Chen K, Yan X, Li SP, Freilich S, Jiang JD. Haoranjiania flava gen. nov., sp. nov., a new member of the family Chitinophagaceae, isolated from activated sludge. Int J Syst Evol Microbiol. 2016 Nov;66(11):4686-4691. doi: 10.1099/ijsem.0.001411. PubMed PMID: 27958192.

4: Verwer EE, Zegers CM, van Elmpt W, Wierts R, Windhorst AD, Mottaghy FM, Lambin P, Boellaard R. Pharmacokinetic modeling of a novel hypoxia PET tracer [(18)F]HX4 in patients with non-small cell lung cancer. EJNMMI Phys. 2016 Dec;3(1):30. PubMed PMID: 27957730.

5: Zinsmeister J, Lalanne D, Terrasson E, Chatelain E, Vandecasteele C, Vu BL, Dubois-Laurent C, Geoffriau E, Signor CL, Dalmais M, Gutbrod K, Dörmann P, Gallardo K, Bendahmane A, Buitink J, Leprince O. ABI5 Is a Regulator of Seed Maturation and Longevity in Legumes. Plant Cell. 2016 Nov;28(11):2735-2754. PubMed PMID: 27956585.

6: de Jong TD, Blits M, de Ridder S, Vosslamber S, Wolbink G, Nurmohamed MT, Verweij CL. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Res Ther. 2016 Dec 12;18(1):290. PubMed PMID: 27955694.

7: Tokuhara M, Gouda Y, Saito Y, Shimzu T, Minowada S, Sasajima K, Takeda Y, Thao LB, Vu HA, Sato Y. Gastrointestinal stromal tumor (GIST) that showed double new malignancies during imatinib therapy: A case report. J Clin Oncol. 2008 May 20;26(15_suppl):21517. PubMed PMID: 27951383.

8: Voorhees PM, Manges RF, Sonneveld P, Somlo G, Jagannath S, Zweegman S, Munteanu M, Vermeulen JT, Xie H, Orlowski RZ. Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM). J Clin Oncol. 2008 May 20;26(15_suppl):8593. PubMed PMID: 27951163.

9: Garrett CR, Siu LL, El-Khoueiry AB, Buter J, Rocha-Lima CM, Marshall JL, Kollia G, Velasquez L, Syed S, Feltquate D. A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy. J Clin Oncol. 2008 May 20;26(15_suppl):4111. PubMed PMID: 27951033.

10: Bastiaannet E, Wobbes T, Meijer S, Hoekstra HJ. Change in treatment as result of FDG-PET and CT in clinically stage III melanoma patients: A prospective study in 221 patients. J Clin Oncol. 2008 May 20;26(15_suppl):9069. PubMed PMID: 27950860.

11: Armstrong DK, Bicher A, Coleman RL, Gibbon DG, Glenn D, Old L, Senzer NN, Schneeweiss A, Verheijen RH, White AJ, Weil S. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse. J Clin Oncol. 2008 May 20;26(15_suppl):5500. PubMed PMID: 27950812.

12: Nogova L, Zander T, Gross SH, Dimitrijevic S, Schmidt K, Thomas RK, Dietlein M, Giaccone G, Hoekstra OS, Wolf J. Pharmacodynamics of RAD001 measured by early FDG PET in patients with recurrent NSCLC. J Clin Oncol. 2008 May 20;26(15_suppl):14616. PubMed PMID: 27950286.

13: Kantarjian HM, Giles FJ, Hochhaus A, Bhalla KN, Ossenkoppele GJ, Gattermann N, Haque A, Gallagher N, Castagnetti F, le Coutre P. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results. J Clin Oncol. 2008 May 20;26(15_suppl):7010. PubMed PMID: 27949982.

14: Bruemmendorf TH, Cervantes F, Kim D, Chandy M, Fischer T, Hochhaus A, Liu D, Ossenkoppele GJ, Hewes B, Cortes JE. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol. 2008 May 20;26(15_suppl):7001. PubMed PMID: 27949961.

15: Langenberg M, van Herpen CM, De Bono JS, Unger C, Schellens JH, Hoekman K, Blum HE, Le Maulf F, Fielding A, Voest EE. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib. J Clin Oncol. 2008 May 20;26(15_suppl):3555. PubMed PMID: 27949661.

16: Steegmann JL, Michallet M, Morra E, Marin D, Ossenkoppele GJ, Verhoef G, Kühr T, Björeman M, Sterckx M, Cerri K. Imatinib use in chronic phase CML in clinical practice: the UNIC study. J Clin Oncol. 2008 May 20;26(15_suppl):7077. PubMed PMID: 27949618.

17: Giaccone G, Smit EF, van Groeningen C, Hogedoorn PC. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol. 2008 May 20;26(15_suppl):14665. PubMed PMID: 27949481.

18: Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR. Time-course MALDI-TOF-MS serum peptide profiling of non-small cell lung cancer patients treated with bortezomib, cisplatin and gemcitabine. J Clin Oncol. 2008 May 20;26(15_suppl):8007. PubMed PMID: 27949004.

19: van den Boogaart V, de Langen A, Groen HJ, Marcus J, Kappert P, Backes W, Brans B, Hoekstra O, Dingemans AC, Smit EF. A phase II study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC): Predictive value of molecular imaging. J Clin Oncol. 2008 May 20;26(15_suppl):8055. PubMed PMID: 27948943.

20: Smit EF, Groen HJ, Smit HJ, Biesma B, Eppinga P, Dingemans AC, van Walree NC, Vincent A, van Zandwijk N; NVALT.. A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)- NVALT 7. J Clin Oncol. 2008 May 20;26(15_suppl):8050. PubMed PMID: 27948939.

VU 0361737

100.0mg / USD 450.0